Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes
Sponsor: Hawler Medical University
Summary
This study compared the impacts of empagliflozin-metformin, sitagliptin-metformin, and metformin monotherapy in treatment-naive overweight or obese adults with newly diagnosed type 2 diabetes mellitus in Erbil, Iraq. The study monitored participants for 12 weeks. It determined changes in serum omentin-1, resistin, glycemic markers, and anthropometric measures.
Official title: Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Serum Omentin 1 and Resistin in Treatment Naive Obese Patients With Type 2 Diabetes: A Clinical Prospective Study
Key Details
Gender
All
Age Range
35 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
186
Start Date
2024-11-15
Completion Date
2025-11-27
Last Updated
2026-04-15
Healthy Volunteers
No
Conditions
Interventions
Empagliflozin-Metformin
Oral empagliflozin in combination with metformin at standard approved doses, given for 3 months to adults with type 2 diabetes mellitus.
Sitagliptin-Metformin
Oral sitagliptin in combination with metformin at standard approved doses, given for 12 weeks to adults with type 2 diabetes mellitus.
Metformin
Oral metformin monotherapy at standard approved doses, given for 3 months to adults with type 2 diabetes mellitus.
Locations (1)
Galyawa Teaching Center for Diabetes and Endocrinology
Erbil, Iraq